Difference between revisions of "Deferiprone (Ferriprox)"
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
(updated content) |
||
| Line 1: | Line 1: | ||
'''FDA approved 10/14/2011''' | '''FDA approved 10/14/2011''' | ||
| + | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Iron chelating agent; binds with ferric ions and forms neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values. Deferiprone has higher binding affinity for iron than other metals such as copper, aluminum, and zinc.<ref name="insert">[http://www. | + | Class/mechanism: Iron chelating agent; binds with ferric ions and forms neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values. Deferiprone has higher binding affinity for iron than other metals such as copper, aluminum, and zinc.<ref name="insert">[http://www.ferriprox.com/us/pdf/ferriprox_full_pi.pdf Deferiprone (Ferriprox) package insert]</ref><ref>[[Media:Deferiprone.pdf | Deferiprone (Ferriprox) package insert (locally hosted backup)]]</ref><ref>[http://www.ferriprox.com Ferriprox manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 8: | Line 9: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | + | *[http://www.ferriprox.com/us/pdf/ferriprox_full_pi.pdf#page=9 Deferiprone (Ferriprox) package insert pages 9-12]<ref name="insert"></ref> | |
| + | *[http://www.uptodate.com/contents/deferiprone-patient-drug-information Deferiprone (Ferriprox) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/deferiprone-patient-drug-information Deferiprone (Ferriprox) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Hematology medications]] | ||
| + | [[Category:Chelators]] | ||
Revision as of 19:08, 14 October 2012
FDA approved 10/14/2011
General information
Class/mechanism: Iron chelating agent; binds with ferric ions and forms neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values. Deferiprone has higher binding affinity for iron than other metals such as copper, aluminum, and zinc.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Deferiprone (Ferriprox) package insert pages 9-12[1]
- Deferiprone (Ferriprox) patient drug information (UpToDate)[4]